CAMBRIDGE, MA / ACCESS Newswire / July 30, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the European Commission ...

The FDA greenlit multiple new drugs this month and issued some notable label expansions including for Eli Lilly’s Kisunla.

The company last reported total revenues of $108M in Q1, down 35.3% Y/Y due to lower net product sales, particularly its ...

Despite efforts to spare employees by scaling back R&D and reducing operating costs by roughly $1.5 billion over the next two ...

Moderna (MRNA) stock in focus as the company plans to cut 10% of its workforce by 2025 amid cost-saving efforts. Read more ...

Moderna has received marketing authorisation from the European Commission for its updated COVID-19 vaccine, Spikevax, which ...

Moderna (Nasdaq: MRNA) has secured European clearance for its latest version of Spikevax (elasomeran) for individuals aged ...

Seventeen experts ousted from a U.S. vaccine committee are expressing little faith in what the panel has become. U.S. Health ...

President Donald Trump has downplayed the influence of Laura Loomer, a right-wing provocateur known for her incendiary social ...

Moderna’s LP.8.1-adapted COVID-19 vaccine has been recommended by the European Medicines Agency (EMA)’s human medicines ...

This risky biotech company faces significant challenges ahead. But it has already proven its worth and may be able to do so ...